Key result
Reactive oxygen species generation is a central mechanism underlying adverse cardiac remodelling and subclinical diastolic dysfunction, which affects up to 75% of optimally controlled diabetics.
Why the study?
Does therapeutic targeting of ROS signalling prevent or delay heart failure development in diabetic cardiomyopathy?
Does therapeutic targeting of ROS signalling prevent or delay heart failure development in diabetic cardiomyopathy?
Targeting reactive oxygen species signaling pathways offers a potential therapeutic strategy to prevent or delay the progression of diabetic cardiomyopathy to heart failure.
Answers are grounded in this paper and cite their sources.
ROS targeting merits trials in diabetic cardiomyopathy; leaves open whether it prevents heart failure progression.
Despite being first described 45 years ago, the existence of a distinct diabetic cardiomyopathy remains controversial. Nonetheless, it is widely accepted that the diabetic heart undergoes characteristic structural and functional changes in the absence of ischaemia and hypertension, which are independently linked to heart failure progression and are likely to underlie enhanced susceptibility to stress. A prominent feature is marked collagen accumulation linked with inflammation and extensive extracellular matrix changes, which appears to be the main factor underlying cardiac stiffness and subclinical diastolic dysfunction, estimated to occur in as many as 75% of optimally controlled diabetics. Whether this characteristic remodelling phenotype is primarily driven by microvascular dysfunction or alterations in cardiomyocyte metabolism remains unclear. Although hyperglycaemia regulates multiple pathways in the diabetic heart, increased reactive oxygen species (ROS) generation is thought to represent a central mechanism underlying associated adverse remodelling. Indeed, experimental and clinical diabetes are linked with oxidative stress which plays a key role in cardiomyopathy, while key processes underlying diabetic cardiac remodelling, such as inflammation, angiogenesis, cardiomyocyte hypertrophy and apoptosis, fibrosis and contractile dysfunction, are redox sensitive. This review will explore the relative contributions of the major ROS sources (dysfunctional nitric oxide synthase, mitochondria, xanthine oxidase, nicotinamide adenine dinucleotide phosphate oxidases) in the diabetic heart and the potential for therapeutic targeting of ROS signalling using novel pharmacological and non-pharmacological approaches to modify specific aspects of the remodelling phenotype in order to prevent and/or delay heart failure development and progression.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2017) conducted a review in Diabetic cardiomyopathy. Therapeutic targeting of ROS signalling was evaluated. Reactive oxygen species generation is a central mechanism underlying adverse cardiac remodelling and subclinical diastolic dysfunction, which affects up to 75% of optimally controlled diabetics.
Synapse has enriched 10 related papers. Consider them for comparative context: